Replies to post #357082 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

Dr.M. is declaring a new field of BIOMED study (IMO). CNS Biomed treatment to be known as (SIGMA CEPTOR). This is a massive new initiative to be driven by a tiny Biotech firm. First stages will include linking and treatments for various CNS indications already underway followed by a WW universe of indications, including rare diseases, some as yet unknown.

A Global Burden of Disease study shows that Alzheimer's disease and other dementias are amongst the 3 most burdensome neurological disorders in the U.S. CNS disorders impact a large number of people with a variety of different cultures and personal backgrounds. From infants to the elderly, we are dedicated to addressing the devastating impact of neurological disorders through our proprietary SIGMACEPTOR™ discovery platform.

A large body of evidence indicates that sigma-1 receptors (SIGMAR1) are important drug targets for a number of neurological disorders. SIGMAR1 are enriched in the central nervous system (CNS) and are the target for the orally available ANAVEX®2-73.

https://www.anavex.com/letter-from-the-ceo